Neuromuscular Disorders
Volume 20, Issue 4 , Pages 283-289 , April 2010

162nd ENMC International Workshop: Disorders of muscle lipid metabolism in adults 28–30 November 2008, Bussum, The Netherlands

  • Pascal Laforêt

      Affiliations

    • Centre de Référence de Pathologie neuromusculaire Paris-Est, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
    • Corresponding Author InformationCorresponding author. Address: Centre de référence de Pathologie neuromusculaire Paris-Est, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 47-83 boulevard de l’Hôpital, 75651 Paris Cedex 13, France. Tel.: +33 142163776; fax: +33 142163793.
    • ,
  • Christine Vianey-Saban

      Affiliations

    • Service Maladies Héréditaires du Métabolisme, Centre de Biologie et de Pathologie Est, CHU Lyon et INSERM U820, 69677 Bron Cedex, France
    • ,
  • John Vissing

      Affiliations

    • Neuromuscular Clinic and Research Unit, Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark

References 

  1. Tein I, Bukovac SW, Xie ZW. Characterization of the human plasmalemmal carnitine transporter in cultured skin fibroblasts. Arch Biochem Biophys. 1996;329:145–155
  2. Angelini C. Disorders of lipid metabolism. In: Mastaglia FL, Hilton-Jones D, editors. Handbook of clinical neurology, vol. 46. Elsevier; 2007. p. 182–91.
  3. Lefèvre C, Jobard F, Caux F, et al. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin–Dorfman syndrome. Am J Hum Genet. 2001;69:1002–1012
  4. Fischer J, Lefevre C, Morava E, et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet. 2007;39:28–30
  5. Roe CR, Roe DS. Recent developments in the investigation of inherited metabolic disorders using cultured human cells. Mol Gen Metab. 1999;68:243–257
  6. Thuillier L, Rostane H, Droin V, et al. Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 deficiency. Hum Mutat. 2003;5:493–501
  7. Noensie EN, Dietz HC. A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat Biotechnol. 2001;19:434–439
  8. Das AM, Fingerhut R, Wanders RJ, Ullrich K. Secondary respiratory chain defect in a boy with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: possible diagnostic pitfalls. Eur J Pediatr. 2000;159:243–246
  9. Tyni T, Majander A, Kalimo H, Rapola J, Pihko H. Pathology of skeletal muscle and impaired respiratory chain function in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency with the G1528C mutation. Neuromuscul Disord. 1996;6:327–337
  10. García-Silva MT, Campos Y, Ribes A, et al. Encephalopathy, petechiae, and acrocyanosis with ethylmalonic aciduria associated with muscle cytochrome c oxidase deficiency. J Pediatr. 1994;125:843–844
  11. Gempel K, Topaloglu H, Talim B, et al. The myopathic form of coenzyme Q deficiency is caused by mutations in the electron-transferring flavoprotein dehydrogénase (ETFDH) gene. Brain. 2007;130:2037–2044
  12. Ørngreen MC, Nørgaard MG, Sacchetti M, van Engelen BGM, Vissing J. Fuel utilization in patients with very-long-chain acyl-coenzyme A dehydrogenase deficiency. Ann Neurol. 2004;56:279–282
  13. Ørngreen MC, Dunø M, Ejstrup R, et al. Fuel utilization in subjects with carnitine palmitoyl-transferase 2 gene mutations. Ann Neurol. 2005;57:60–66
  14. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet. 1999;21(1):91–94
  15. Di Donato S, Taroni F. Disorders of lipid metabolism. In: Engel AG, editor. Myology. McGraw-Hill Professional Publishing. 2004. p. 1587–615.
  16. DiMauro S, Melis-DiMauro PM. Muscle carnitine palmitoyltransferase deficiency and myoglobinuria. Science. 1973;182:929–931
  17. Bertrand C, Largillière C, Zabot MT, Mathieu M, Vianey-Saban C. Very long chain acyl-CoA dehydrogenase deficiency: identification of a new inborn error of mitochondrial fatty acid oxidation in fibroblasts. Biochim Biophys Acta. 1993;1180:327–329
  18. Vianey-Saban C, Divry P, Brivet M, et al. Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta. 1998;269:43–62
  19. Laforêt P, Acquaviva-Bourdain C, Rigal O, et al. Diagnostic assessment and long-term follow-up of 13 patients with very long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord. 2009;19(5):324–329
  20. Andresen BS, Vianey-Saban C, Bross P, et al. The mutational spectrum in very long-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 1996;19(2):169–172
  21. Andresen BS, Olpin S, Poorthuis BJHM, et al. Clear correlation of genotype with disease phenotype in very-long-chain Acyl-CoA dehydrogenase deficiency. Am J Hum Genet. 1999;64:478–494
  22. Horvath R, Schneiderat P, Schoser BG, et al. Coenzyme Q10 deficiency and isolated myopathy. Neurology. 2006;66(2):253–255
  23. Chanarin I, Patel A, Slavin G, Wills EJ, Andrews TM, Stewart G. Neutral-lipid storage disease: a new disorder of lipid metabolism. Br Med J. 1975;1(5957):553–555
  24. Bruno C, DiMauro S. Lipid storage myopathies. Curr Opin Neurol. 2008;21:601–606
  25. Ørngreen MC, Ejstrup R, Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology. 2003;61:559–561
  26. Vissing J, Di Donato S, Taroni F. Metabolic myopathies. In:  Karpati G,  Hilton-Jones D,  Bushby K,  Griggs RC editor. Disorders of voluntary muscles. 8th ed.. UK: Cambridge University Press; 2009;p. 390–407[chapter 20]
  27. Olsen RK, Olpin SE, Andresen BS, et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain. 2007;130:2045–2054
  28. Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002;110:259–269
  29. Roe CR, Yang BZ, Brunengraber H, Roe DS, Wallace M, Garritson BK. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology. 2008;71:260–264
  30. Chapoy PR, Angelini C, Brown WJ, Stiff JE, Shug AL, Cederbaum SD. Systemic carnitine deficiency – a treatable inherited lipid-storage disease presenting as Reye’s syndrome. N Engl J Med. 1980;303(24):1389–1394
  31. Lamhonwah AM, Olpin SE, Pollitt RJ, et al. Novel OCTN2 mutations: no genotype–phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am J Med Genet. 2002;111:271–284
  32. Liebig M, Gyenes M, Brauers G, et al. Carnitine supplementation induces long-chain acylcarnitine production – studies in the VLCAD-deficient mouse. J Inherit Metab Dis. 2006;29(2–3):343–344
  33. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 1999;354:141–148[Review]
  34. Djouadi F, Aubey F, Schlemmer D, Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab. 2005;90(3):1791–1797
  35. Djouadi F, Aubey F, Schlemmer D, et al. Bezafibrate increases very long chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblats and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet. 2005;18:2495–2703
  36. Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med. 2009;360(8):838–840
  37. Jorgensen SB, Rose AJ. How is AMPK activity regulated in skeletal muscles during exercise?. Front Biosci. 2008;13:5589–5604
  38. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415(6869):339–343
  39. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288–1295
  40. Taivassalo T, Gardner JL, Taylor RW, et al. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain. 2006;129(Pt 12):3391–3401
  41. Jeppesen TD, Schwartz M, Olsen DB, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain. 2006;129(Pt 12):3402–3412
  42. Haller RG, Wyrick P, Taivassalo T, Vissing J. Aerobic conditioning: an effective therapy in McArdle’s disease. Ann Neurol. 2006;59:922–928

PII: S0960-8966(10)00047-7

doi: 10.1016/j.nmd.2010.01.010

Neuromuscular Disorders
Volume 20, Issue 4 , Pages 283-289 , April 2010

Article Tools

* Image Usage & Resolution